Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
CDK2/CyclinE2 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
9 nM 11 nM 15 nM >10 μM >10 μM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MXrLbY5ie2ViQYPzZZk> MVGyOEBp M2nnVmlvcGmkaYTpc44hd2ZiQ1TLOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHJjKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFIh|ryP M1fYWFI1PjRzMUCz
COLO205 M4G0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;aXlczKGh? MnH5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> M{TLdFI1PjRzMUCz
U937 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLCb|ZKPzJiaB?= NFLnNYZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO NUnzdJpYOjR4NEGxNFM>
MOLM13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi3NkBp NY[4T5B7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? MkH6NlQ3PDFzMEO=
MOLM13 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K4c|czKGh? MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO NITZW4UzPDZ2MUGwNy=>
MDA-MB-435 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOyOEBp NFrNdHpKSzVyPUCuNVYh|ryP MVKxOVgxOTh|MR?=
K562 MnnnR5l1d3SxeHnjJGF{e2G7 MmXVPVYhcA>? Mk\CSG1UVw>? MkizTWM2OD1{IN88US=> NVTBXXJkOjR2MUe1OlY>
DU145 MmPyR5l1d3SxeHnjJGF{e2G7 MnnrPVYhcA>? NUX5TYN7TE2VTx?= MWDJR|UxRTdwNTFOwG0> MXiyOFQyPzV4Nh?=
MDA-MB-231 NEXn[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG1cXMyKM7:TR?= NYfYRZNDOjRiaB?= MV7EUXNQ NG\ydJhE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> NGf3O4wzPDRzN{W2Oi=>
MCF7 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf1NUDPxE1? Ml;kNlQhcA>? M2PxXmROW09? MlnoR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl NXHhOJR2OjR2MUe1OlY>
MCF7 NV\0fYRNU2mwYYPlJGF{e2G7 NWnLendKPSEQvF2= NEfzc4UzPCCq NWrjcWZYTE2VTx?= M4XucWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= MmLYNlQ1OTd3Nk[=
MDA-MB-231 M3nlNmtqdmG|ZTDBd5NigQ>? MlLGOUDPxE1? MVmyOEBp M2\4XGROW09? NXz2N5dLUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> NXvGc4lEOjR2MUe1OlY>
MDA-MB-231 NUHRZldyTnWwY4Tpc44hSXO|YYm= MXmxMVExKM7:TR?= M{KwNVI1KGh? NF[3R2VFVVOR NHO4cJZld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= M2P1OVI1PDF5NU[2
MCF7 NYq2ZY5MTnWwY4Tpc44hSXO|YYm= MVWxMVExKM7:TR?= MXiyOEBp MnXRSG1UVw>? NEHTbY9ld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= MYGyOFQyPzV4Nh?=
MDA-MB-231 NGjrSXNHfW6ldHnvckBCe3OjeR?= NWfKPJEzOC53LUGg{txO NVnQUJp3PDhiaB?= MV\EUXNQ MmD1bIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> M3vaOFI1PDF5NU[2
MCF7 NYPo[FRMTnWwY4Tpc44hSXO|YYm= MVGwMlUuOSEQvF2= NGrENFM1QCCq MkDYSG1UVw>? M2K3dIhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm M4rXcVI1PDF5NU[2
697 M4XQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF2OD6zPEBvVQ>? NIDjdXVUSU6JRWK=
P12-ICHIKAWA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTl4LkC0JI5O MnPuV2FPT0WU
NB69 NHjKU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\6fppKSzVyPUG2NU45KG6P MXHTRW5ITVJ?
EoL-1 NYrsd2tJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{mzWmlEPTB;MUi3MlI3KG6P MmCzV2FPT0WU
BHT-101 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4TWM2OD1zOUiuNlUhdk1? NXG4e|huW0GQR1XS
SK-NEP-1 NG\2UHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;EUWlEPTB;MkKwMlAzKG6P MWPTRW5ITVJ?
MHH-NB-11 NEDEe|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ{MD6xPUBvVQ>? M{\JXXNCVkeHUh?=
AsPC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnlXnJGUUN3ME2yOVIvPTNibl2= NGjLS2ZUSU6JRWK=
ES1 NWSxNZdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTNTVM2UUN3ME2yOVYvOjVibl2= MoTpV2FPT0WU
LAMA-84 NHexdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\PTWM2OD1{NUiuNVkhdk1? MVjTRW5ITVJ?
MOLT-16 NIPqflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn1U5BGUUN3ME2yOVgvPDlibl2= MnPPV2FPT0WU
ES7 M{S3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ5Mz6wPUBvVQ>? NXzNfFdvW0GQR1XS
KY821 M{\pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljaTWM2OD1|MUSuNUBvVQ>? NULOc5B2W0GQR1XS
RT-112 M13Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOyTWM2OD1|MkGuNFUhdk1? M{C4UnNCVkeHUh?=
HL-60 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG0UYRKSzVyPUO0NE43PiCwTR?= MnK5V2FPT0WU
MOLT-4 NHvkWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rPSmlEPTB;M{S1MlE{KG6P MlTsV2FPT0WU
KARPAS-45 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXxTWM2OD1|N{[uNVYhdk1? MVfTRW5ITVJ?
SK-N-AS MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN6Nz64N{BvVQ>? NVjYfmp6W0GQR1XS
CTB-1 MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfvTWM2OD12MEWuNFIhdk1? MXfTRW5ITVJ?
NKM-1 NUn6VXlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXBTWM2OD12MUGuPFkhdk1? NHnmSXBUSU6JRWK=
HTC-C3 NUfFXoZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jtOGlEPTB;NEOyMlk2KG6P MnSxV2FPT0WU
BE-13 NX7XVm44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfjTWM2OD12NESuNlchdk1? MmXXV2FPT0WU
KOSC-2 NUC0N5k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzJNVVKSzVyPUS2Ok46KG6P MUHTRW5ITVJ?
NB14 M{PR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S3TmlEPTB;NEizMlU5KG6P M1XzUHNCVkeHUh?=
CAL-27 M{XkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTR7ND61PUBvVQ>? MknmV2FPT0WU
H9 Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTR7NT60N{BvVQ>? M4W2[HNCVkeHUh?=
RS4-11 NVmxepFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTVyND63N{BvVQ>? MUfTRW5ITVJ?
PA-1 M3rWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrTVZZKSzVyPUWwPU45PiCwTR?= MnXnV2FPT0WU
MV-4-11 NYf4WoViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPrU2FKSzVyPUWxN{45PSCwTR?= MlvDV2FPT0WU
OS-RC-2 NIXhXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTV{MT62NkBvVQ>? Mn\yV2FPT0WU
RPMI-8226 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjtTWM2OD13Mk[uPFYhdk1? M3jBVHNCVkeHUh?=
HGC-27 NF7OdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSzTWM2OD13NkSuPVkhdk1? M2XkR3NCVkeHUh?=
CHP-212 MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnmTWM2OD13OUOuOVkhdk1? M3HvUXNCVkeHUh?=
NB10 NWqxT5hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu1TWM2OD13OUmuNVghdk1? NHjyXpFUSU6JRWK=
HH MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTV7OT60N{BvVQ>? NW\TPWRuW0GQR1XS
EW-16 M1mzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxWmlEPTB;NkCzMlUzKG6P MWjTRW5ITVJ?
ES8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZyNT6yNUBvVQ>? MX;TRW5ITVJ?
HAL-01 MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH33UmFKSzVyPU[wOU43PyCwTR?= MUjTRW5ITVJ?
A204 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTZ|Mz65NUBvVQ>? MUHTRW5ITVJ?
MHH-PREB-1 NVP2WIlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jucWlEPTB;NkO2Mlk6KG6P M{\1dXNCVkeHUh?=
EM-2 M1GxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TEbWlEPTB;NkWwMlY1KG6P MnvnV2FPT0WU
BV-173 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofxTWM2OD14NUKuOFghdk1? MmP5V2FPT0WU
ONS-76 NF7ZNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnObGVCUUN3ME22O|cvQDJibl2= MnriV2FPT0WU
KM-H2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH65bZFKSzVyPU[5OU42PCCwTR?= NIXt[WFUSU6JRWK=
D-263MG NF7oWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nRN2lEPTB;N{G3MlEzKG6P NX7U[It3W0GQR1XS
ES3 NEfCRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFWZZKSzVyPUeyPE46OyCwTR?= MlfyV2FPT0WU
VA-ES-BJ MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnMc3hNUUN3ME23N|IvOjdibl2= M4PEU3NCVkeHUh?=
NBsusSR NYrlR446T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m3b2lEPTB;N{SyMlk6KG6P M3T3WnNCVkeHUh?=
NCI-H520 NETMSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTd2Nj61NkBvVQ>? M3HVTHNCVkeHUh?=
ES5 NV6zUWN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ztUGlEPTB;N{WyMlghdk1? MXfTRW5ITVJ?
T-24 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3xXZBKSzVyPUe3PE44OSCwTR?= M32ydnNCVkeHUh?=
SW962 NWnr[VJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGWwcIFKSzVyPUiwPE43OyCwTR?= M{HoVHNCVkeHUh?=
EW-3 NV36elA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn0RZFqUUN3ME24NFgvPzZibl2= MmLSV2FPT0WU
RXF393 NFPWVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK3TWM2OD16MUKuO|khdk1? MmD0V2FPT0WU
U251 NWrjSm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf5TVY6UUN3ME24NVMvQDhibl2= M3ixZXNCVkeHUh?=
CAMA-1 NETKSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f0[2lEPTB;OEOzMlk1KG6P MnjjV2FPT0WU
JVM-3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTh3MT63PEBvVQ>? M2jlNXNCVkeHUh?=
COLO-800 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nwfmlEPTB;OEm3Mlc5KG6P M{nSZXNCVkeHUh?=
OVCAR-5 NWfQ[G12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vLdWlEPTB;OUCwMlEhdk1? NXyxVVR4W0GQR1XS
LB1047-RCC M4jEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTl{Nz61OkBvVQ>? MX7TRW5ITVJ?
SW954 NHHjSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjEfplKSzVyPUmyPU41OSCwTR?= NVrSdIdSW0GQR1XS
J-RT3-T3-5 MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm1dGRKSzVyPUmzOk4xPiCwTR?= MYXTRW5ITVJ?
Mewo MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLUTWM2OD17M{[uOkBvVQ>? MUXTRW5ITVJ?
NCI-H1770 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTl2MD61OUBvVQ>? M3;XPHNCVkeHUh?=
HO-1-N-1 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXlTWM2OD17NkKuPFEhdk1? NH34NHlUSU6JRWK=
HSC-3 MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTl4Nj60PEBvVQ>? MY\TRW5ITVJ?
TYK-nu M1LCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHRTWM2OD17OUiuNlUhdk1? NF21ZVRUSU6JRWK=
KYSE-150 MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3LTWM2OD1zLkCwNFc3KM7:TR?= MWnTRW5ITVJ?
SN12C MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFwMEC4O|Uh|ryP MXXTRW5ITVJ?
MOLT-13 NIrqTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFwMEG0NlEh|ryP NVLIN|ZuW0GQR1XS
TE-11 M{X4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwMES4NVIh|ryP MVrTRW5ITVJ?
DB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj4TWM2OD1zLkC3Nlc{KM7:TR?= NYXlfFY3W0GQR1XS
CAL-39 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwMEe1NlIh|ryP MkfoV2FPT0WU
A3-KAW NF7SdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXS4TYJQUUN3ME2xMlA5PDB6IN88US=> MofpV2FPT0WU
CHP-134 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWxTWM2OD1zLkGxPFA4KM7:TR?= NU\iNYxbW0GQR1XS
TGW Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHDTWM2OD1zLkGyN|k2KM7:TR?= M3zGbHNCVkeHUh?=
QIMR-WIL NVfUc2d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDKTWM2OD1zLkGzNVM1KM7:TR?= NFXsPGRUSU6JRWK=
NCI-SNU-1 NUDyRVgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwMU[zOVQh|ryP MVLTRW5ITVJ?
CGTH-W-1 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfmb3VKSzVyPUGuNVcyQDZizszN NIf5RWtUSU6JRWK=
MHH-ES-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwMUe5PFYh|ryP NXTjVYRsW0GQR1XS
LB2241-RCC MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmxUYE6UUN3ME2xMlE5PjJizszN M1jQTXNCVkeHUh?=
ML-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jWO2lEPTB;MT6yNFc{PCEQvF2= MWPTRW5ITVJ?
COR-L23 MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm5TJhKSzVyPUGuNlI6OzNizszN NVrheo5TW0GQR1XS
BFTC-905 NFr5VZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzDNWNKSzVyPUGuNlQzPjdizszN NFT2c|VUSU6JRWK=
Hs-578-T MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwMkW4NVch|ryP MXzTRW5ITVJ?
KG-1 M2ntZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwMk[2PFYh|ryP NXvybpZGW0GQR1XS
HEL M321OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDUboFKSzVyPUGuNlk{OzhizszN MonjV2FPT0WU
A549 NH71NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nYVWlEPTB;MT6yPVM6QSEQvF2= M2H4SXNCVkeHUh?=
COLO-741 MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPqUIo2UUN3ME2xMlMzODh7IN88US=> NGTHSIVUSU6JRWK=
PC-3 NUjGeZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPTS2R3UUN3ME2xMlM2OjJzIN88US=> MYfTRW5ITVJ?
HOS NX3BNXp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPKfnNKSzVyPUGuN|UzQTZizszN M2nPdXNCVkeHUh?=
HT-1080 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDSPHNKSzVyPUGuN|c2OTlizszN MXvTRW5ITVJ?
TE-8 NHnlUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLweYlKSzVyPUGuOFE4PzRizszN M1TrXHNCVkeHUh?=
BHY MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jub2lEPTB;MT60OlkzOyEQvF2= M4na[HNCVkeHUh?=
BB65-RCC NGjFc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;GN4FKSzVyPUGuOVA2OjhizszN M3XsTHNCVkeHUh?=
HN NFviZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnBTWM2OD1zLkW0NFcyKM7:TR?= MUjTRW5ITVJ?
NCI-H441 M3m4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHNTWM2OD1zLkW0PVA4KM7:TR?= MXjTRW5ITVJ?
RPMI-8866 M{jUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX0eoZVUUN3ME2xMlU5PTB5IN88US=> M1fpbHNCVkeHUh?=
CAL-62 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2OxZ2lEPTB;MT62NFg3OiEQvF2= NYXqbYRIW0GQR1XS
MG-63 MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljUTWM2OD1zLk[xPFE{KM7:TR?= NGLtVGRUSU6JRWK=
SK-LU-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNkKxOVIh|ryP NIPqemJUSU6JRWK=
BCPAP MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwNk[0OVch|ryP NWftSYQxW0GQR1XS
22RV1 M3T6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\WTWM2OD1zLk[3PFQ{KM7:TR?= M4LQVnNCVkeHUh?=
T47D NGj0VGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLKcHVKSzVyPUGuOlgxPjFizszN NWTtPZpzW0GQR1XS
MSTO-211H M33JWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vNWWlEPTB;MT62PVYxOyEQvF2= NFeyRnFUSU6JRWK=
DEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP5R|AyUUN3ME2xMlcxOjd|IN88US=> NV22NnBzW0GQR1XS
H4 NInJdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LZcmlEPTB;MT63N|IyOiEQvF2= MWLTRW5ITVJ?
CAL-51 M{LD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLIb4ZKSzVyPUGuO|Q5PTVizszN NG\SUIZUSU6JRWK=
ABC-1 NWfsdGI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwN{i1PFIh|ryP MUTTRW5ITVJ?
MZ2-MEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwN{m1OFIh|ryP Mn3uV2FPT0WU
YKG-1 NF3mVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fuemlEPTB;MT64NVA3OSEQvF2= Mn;kV2FPT0WU
KM12 NUL6WlVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHhfG95UUN3ME2xMlgyPjB{IN88US=> NXHaT3NQW0GQR1XS
L-363 MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHSdFNKSzVyPUGuPFc1OTJizszN NFv1U2RUSU6JRWK=
KU812 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwOEmyPFIh|ryP NXTQ[ItPW0GQR1XS
LOXIMVI NF3tV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwOUGyNlgh|ryP MXnTRW5ITVJ?
G-401 NYi3TnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmwdGpOUUN3ME2xMlkzPDJ6IN88US=> MXPTRW5ITVJ?
SW780 M3;Pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwOU[yOFYh|ryP M3vleXNCVkeHUh?=
SW872 NULDbJNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PuSWlEPTB;MT65PFM{KM7:TR?= NUPUUVdJW0GQR1XS
NB7 NEnZNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwOUmzNlMh|ryP NWja[Hg{W0GQR1XS
T98G MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zzUGlEPTB;Mj6wNFY3PiEQvF2= NXO4e4k1W0GQR1XS
SW1710 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHkeIh{UUN3ME2yMlA3QTR3IN88US=> MlK0V2FPT0WU
NCI-H1573 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmwWmdnUUN3ME2yMlA4Ojl6IN88US=> NFnOc4FUSU6JRWK=
KE-37 NVnoPG1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwMEi5OVEh|ryP MW\TRW5ITVJ?
786-0 M3:xeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPwOW5sUUN3ME2yMlE2PDN7IN88US=> MVLTRW5ITVJ?
SAS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7EZoh5UUN3ME2yMlIxOzd2IN88US=> MV7TRW5ITVJ?
CAL-54 Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H0OmlEPTB;Mj6yNFQyOyEQvF2= MmPLV2FPT0WU
SF268 NVrvenRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL6TWM2OD1{LkKzNVIzKM7:TR?= NGDKRW5USU6JRWK=
SW620 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfoTWM2OD1{LkK2NVY6KM7:TR?= M3r2W3NCVkeHUh?=
MN-60 MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjibJFGUUN3ME2yMlMyODZizszN NVvFWYd5W0GQR1XS
EFO-27 M4Tuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuxTIlKSzVyPUKuN|IxPThizszN M3TFRnNCVkeHUh?=
NCI-H747 NWP3fJZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf6TY1IUUN3ME2yMlMzOTl7IN88US=> M2\vb3NCVkeHUh?=
HCC2218 NFXyXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PaNWlEPTB;Mj6zOVM4PCEQvF2= NFLabHJUSU6JRWK=
MIA-PaCa-2 NXrGd5JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPvN|ZqUUN3ME2yMlM3PDN5IN88US=> MnLlV2FPT0WU
SJSA-1 M3Xa[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:2Zm1bUUN3ME2yMlM4Pzl4IN88US=> NHrBWHJUSU6JRWK=
RKO NIXjdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[3TWM2OD1{LkO4OFk3KM7:TR?= NWLPdJNGW0GQR1XS
NB6 NX7ybm9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwNECzO|Qh|ryP MlntV2FPT0WU
ES4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHTTWM2OD1{LkS1OFIzKM7:TR?= M4jyWHNCVkeHUh?=
EGI-1 M3z4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHFTWM2OD1{LkS2PFg{KM7:TR?= MWPTRW5ITVJ?
CTV-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW0ZmcyUUN3ME2yMlUzPzd|IN88US=> MlfvV2FPT0WU
NCI-H1355 NIrGVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFmwSZZKSzVyPUKuOVU6PTFizszN NGDkNIxUSU6JRWK=
GT3TKB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke4TWM2OD1{LkW5NVk6KM7:TR?= M3zmTnNCVkeHUh?=
SK-HEP-1 NWLpTJlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXiZm1pUUN3ME2yMlU6OjZ4IN88US=> M4jLZ3NCVkeHUh?=
GAMG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKxfVlKSzVyPUKuOVk{QTRizszN Mle0V2FPT0WU
SK-MES-1 M1XI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTEe|F1UUN3ME2yMlYyQDB|IN88US=> NWnQbppDW0GQR1XS
RO82-W-1 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HXcmlEPTB;Mj62NlA2PyEQvF2= MnPUV2FPT0WU
ECC10 M1vzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX1UpFjUUN3ME2yMlcxOjB4IN88US=> NHv1[m1USU6JRWK=
MCF7 NG[1elJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjBTWM2OD1{LkexOFY1KM7:TR?= MVzTRW5ITVJ?
D-283MED Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG5TWM2OD1{LkeyOFMh|ryP NXnHNpY{W0GQR1XS
RPMI-7951 M17JbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXSTWM2OD1{Lke1Olk1KM7:TR?= M2n5cnNCVkeHUh?=
Ramos-2G6-4C10 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrCSohKSzVyPUKuO|cxQTlizszN NV75eoR3W0GQR1XS
KGN MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\BTWM2OD1{LkixPFg1KM7:TR?= Mne0V2FPT0WU
NUGC-3 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXNTYJ6UUN3ME2yMlgzPTB3IN88US=> NVzGRVloW0GQR1XS
NCI-H292 NYnQRYI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PYcWlEPTB;Mj64OVA2OyEQvF2= M33xZXNCVkeHUh?=
Becker Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTUPGV3UUN3ME2yMlk2QDN{IN88US=> NFzrcppUSU6JRWK=
NCI-H1299 NGDvPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO3TWM2OD1|LkC1NlY{KM7:TR?= M1T3O3NCVkeHUh?=
ETK-1 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwMEW0N{DPxE1? M4\XSnNCVkeHUh?=
TK10 NH7KSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLaTWM2OD1|LkKwNVY2KM7:TR?= MmjiV2FPT0WU
VMRC-RCZ M4rFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLQTYJKSzVyPUOuN|Y1QDhizszN NYi3SmJjW0GQR1XS
YH-13 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTNwNESwO|kh|ryP NGnSdJRUSU6JRWK=
DU-145 Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;hcmlEPTB;Mz60OlI3QSEQvF2= MUDTRW5ITVJ?
SW1088 MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDDT25KSzVyPUOuOFc1PyEQvF2= MXnTRW5ITVJ?
HOP-92 NUjVcYxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnvTFNKSzVyPUOuOVA{PDJizszN MVTTRW5ITVJ?
KP-N-YS MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNkKxN|kh|ryP M4jyc3NCVkeHUh?=
NCI-H460 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPhTWM2OD1|Lk[2O|Mh|ryP NXrGd|NOW0GQR1XS
U-2-OS MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLNXGhYUUN3ME2zMlczPTN3IN88US=> NGjGZ4tUSU6JRWK=
A101D M1Hob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rXR2lEPTB;Mz63Olk{PiEQvF2= MmnjV2FPT0WU
MDA-MB-231 M3jWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPEUIZKSzVyPUOuPFE6PTFizszN NIGxTpFUSU6JRWK=
IST-MES1 M1HaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37ydGlEPTB;Mz64N|Ih|ryP M3ftVHNCVkeHUh?=
COR-L105 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPWU4hJUUN3ME20MlAyQCEQvF2= MmPQV2FPT0WU
NCI-H1437 NIr6e2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrKNZpKSzVyPUSuNFI{ODJizszN NWjqeoJxW0GQR1XS
CAL-85-1 NGnQVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTRwMEK0OlEh|ryP NGjPfXVUSU6JRWK=
MZ1-PC MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTRwMUi1OVYh|ryP MXrTRW5ITVJ?
VM-CUB-1 Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwM{GyPFQh|ryP NYHiZ4FpW0GQR1XS
CHL-1 NInEVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRwM{KxOlkh|ryP NILQV4lUSU6JRWK=
MDA-MB-361 M{\lfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjjZldiUUN3ME20MlM{OTV|IN88US=> MVjTRW5ITVJ?
NCI-H661 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fCOGlEPTB;ND61NFA6OiEQvF2= Mn65V2FPT0WU
EW-11 NUHlTJhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTafJBKSzVyPUSuOVIzOzFizszN Mn\OV2FPT0WU
BEN MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTRwNUK4NVUh|ryP NGjPXmVUSU6JRWK=
BFTC-909 NYPlN49zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LYcmlEPTB;ND61OlI4PSEQvF2= NHXFToZUSU6JRWK=
NCI-H2087 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3sXXNEUUN3ME20MlU5OTZ2IN88US=> NV\Ud3loW0GQR1XS
RVH-421 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRwNk[2PUDPxE1? M4DlZ3NCVkeHUh?=
P30-OHK Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq3TWM2OD12Lk[4NFA5KM7:TR?= NX:4WGNMW0GQR1XS
NCI-H28 M{jYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnyd4RKSzVyPUSuPFE3PjFizszN M2rwZXNCVkeHUh?=
ES6 NGP5ZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PPT2lEPTB;ND64N|AyPiEQvF2= NUTyWWVwW0GQR1XS
769-P M{\KVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\Gcng6UUN3ME20Mlg2QTJ4IN88US=> MmDSV2FPT0WU
OE33 NU\oc49XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvsTppKSzVyPUSuPFgyPjFizszN NHH3V|NUSU6JRWK=
SW982 M3yxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwOUWwOlEh|ryP NIDIZnZUSU6JRWK=
A388 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDa[FRKSzVyPUWuNFI6QDNizszN NFXBWHlUSU6JRWK=
TI-73 NYnJcoZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTVwME[xPVQh|ryP MVHTRW5ITVJ?
HCT-116 NFvsRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDnTWM2OD13LkC5PFg6KM7:TR?= MVvTRW5ITVJ?
HuP-T3 NEXybphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7OcIlKSzVyPUWuNVg4ODlizszN MnL6V2FPT0WU
G-402 M2LrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf6fG1KSzVyPUWuNVk1OTZizszN NHnsNXJUSU6JRWK=
NCI-H1792 MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTVwMkS2NlIh|ryP Mm\hV2FPT0WU
NCI-H209 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi0VHZlUUN3ME21MlI2QTR{IN88US=> NXrZUWdpW0GQR1XS
NCI-H1650 M1;zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTVwM{C2N|Qh|ryP M2PhcXNCVkeHUh?=
LCLC-97TM1 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37McGlEPTB;NT6zNVgxQCEQvF2= MULTRW5ITVJ?
S-117 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrYVoNKSzVyPUWuN|Y6PzZizszN MWrTRW5ITVJ?
GI-ME-N M4nQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWwTWM2OD13LkO5OlgyKM7:TR?= MmPLV2FPT0WU
NCI-H2122 M3n3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12wZWlEPTB;NT60PVM6PyEQvF2= MnHyV2FPT0WU
NCI-H1793 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjuPZFSUUN3ME21MlY4PTl|IN88US=> MX3TRW5ITVJ?
C2BBe1 NGO0RmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi0TWM2OD13LkewNFg5KM7:TR?= NYXvVFFxW0GQR1XS
TE-12 NYLiZ|VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;yTWM2OD13LkiwOVU3KM7:TR?= NX3RS5V1W0GQR1XS
LCLC-103H NVTNZlZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq0TWM2OD13LkmxO{DPxE1? MkjqV2FPT0WU
A673 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXFTWM2OD13LkmxPVMzKM7:TR?= NYnIfIxxW0GQR1XS
BB30-HNC NVz5[Y1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr6V3VKSzVyPUWuPVg{PiEQvF2= NVLBdGhLW0GQR1XS
SF295 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\qOndKSzVyPU[uNFA1OjJizszN MVzTRW5ITVJ?
KU-19-19 NHrYRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXrO3JKSzVyPU[uNFE4OzFizszN NV;pOXpxW0GQR1XS
CFPAC-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LpTmlEPTB;Nj6wOFQ1OyEQvF2= MmnLV2FPT0WU
LoVo MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnsTWM2OD14LkC1NFY{KM7:TR?= NEjzNo1USU6JRWK=
8505C NGnDS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DyVGlEPTB;Nj6wO|U4OyEQvF2= M3XmOHNCVkeHUh?=
GMS-10 NVvIbYxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrZZ5lKSzVyPU[uNVUxODJizszN NHTPSlVUSU6JRWK=
Ca9-22 NXHtVVZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfVdFRKSzVyPU[uNVY4OSEQvF2= NELh[YFUSU6JRWK=
DOK M3\qOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLUdZVKSzVyPU[uNlIxPzJizszN MYXTRW5ITVJ?
FADU Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSyTWM2OD14LkK2NFM6KM7:TR?= M3PGbnNCVkeHUh?=
BxPC-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzXTWM2OD14LkK3N|Ih|ryP M4nVfHNCVkeHUh?=
CAL-33 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1frS2lEPTB;Nj6yPVIxOSEQvF2= M1LxcnNCVkeHUh?=
SHP-77 NYnpWVRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGxS|JPUUN3ME22MlMyPTF{IN88US=> Ml7zV2FPT0WU
LXF-289 M3TCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr1TWM2OD14LkOzOFU2KM7:TR?= MXTTRW5ITVJ?
GB-1 NWW0S5VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M36xfGlEPTB;Nj6zPFIh|ryP NFK5R3ZUSU6JRWK=
KS-1 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33HTGlEPTB;Nj6zPFQ1PyEQvF2= M{HDS3NCVkeHUh?=
D-502MG NXzPTW5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHRfmJKSzVyPU[uOFI{PzZizszN MoTvV2FPT0WU
LAN-6 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZwNUGwNlMh|ryP Mnm5V2FPT0WU
H-EMC-SS MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j2WWlEPTB;Nj61OlE1PyEQvF2= NFPYS4xUSU6JRWK=
LC-2-ad M{\HUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\rSWlEPTB;Nj62NFA4PiEQvF2= NELhdI9USU6JRWK=
NCI-H1693 Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHGZXhKSzVyPU[uOlIzOTVizszN MVXTRW5ITVJ?
SK-N-FI NUPjR5ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XK[WlEPTB;Nj63OVA1PCEQvF2= NVjPeY45W0GQR1XS
D-423MG MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO5OldWUUN3ME22Mlc3OTF5IN88US=> NETwcndUSU6JRWK=
KNS-42 NFHFRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3fGlEPTB;Nj63PFE6PyEQvF2= M1;j[HNCVkeHUh?=
GCT NETuVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrEUXBnUUN3ME22Mlk{QCEQvF2= NXTGPYE3W0GQR1XS
DSH1 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXieWJwUUN3ME23MlA3OzNizszN M1HQOHNCVkeHUh?=
D-247MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnMcVUxUUN3ME23MlA4QDhzIN88US=> MU\TRW5ITVJ?
NCI-SNU-5 NV3BcIVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[y[mhKSzVyPUeuNVg{PzFizszN NXrlVm42W0GQR1XS
TE-6 NGKzfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn0d2p5UUN3ME23MlIxPjBzIN88US=> Mkf4V2FPT0WU
NOMO-1 NI\3c4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W0bmlEPTB;Nz6yNlEzPyEQvF2= NHLuVYhUSU6JRWK=
NB17 NXLkOWdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[5OWlEPTB;Nz6zNFMxQSEQvF2= M{XuTHNCVkeHUh?=
EW-22 NHvJVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTdwM{SzOFgh|ryP NWfHWY01W0GQR1XS
EW-13 NVvBeoVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTN[4lEUUN3ME23MlM2OTZ{IN88US=> M{nyeHNCVkeHUh?=
DOHH-2 NIPwb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\iO|JKSzVyPUeuOFQxOiEQvF2= MmTqV2FPT0WU
TGBC1TKB NGfPOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16ye2lEPTB;Nz60PVg6QSEQvF2= MV;TRW5ITVJ?
GR-ST NX6yNo1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TX[GlEPTB;Nz61NlU6PCEQvF2= Mo\IV2FPT0WU
KYSE-520 NFnOV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHweGZKSzVyPUeuOVU2OTVizszN M3HPWHNCVkeHUh?=
CAPAN-1 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3ieZNKSzVyPUeuOVk2OSEQvF2= MofWV2FPT0WU
HCE-4 MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TTRWlEPTB;Nz62NlI4QSEQvF2= M4XFOHNCVkeHUh?=
MLMA NWrWdG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[2VGlEPTB;Nz62Nlk2PyEQvF2= NYjpd3FRW0GQR1XS
HT-144 M{jLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImxT2xKSzVyPUeuOlU{PjhizszN NXTDUnZ[W0GQR1XS
KYSE-180 NFXJfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojFTWM2OD15LkexNVY6KM7:TR?= MWjTRW5ITVJ?
TE-5 NXrMPGF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXsTWM2OD15Lkm1PVcyKM7:TR?= NH\aTW5USU6JRWK=
IGROV-1 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTdwOUi1OVEh|ryP MWLTRW5ITVJ?
NCI-H1581 M3\yN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF35TmRKSzVyPUiuNFEzKM7:TR?= M3jFWHNCVkeHUh?=
SW1990 M13MXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fkT2lEPTB;OD6wOFY2QSEQvF2= M3nqUHNCVkeHUh?=
EFM-19 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLJTWM2OD16LkC4OVQ2KM7:TR?= MVjTRW5ITVJ?
OGR-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2zTWM2OD16LkSzNFI{KM7:TR?= M4j0[3NCVkeHUh?=
U-118-MG NUXWWFBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwNEO0OlMh|ryP MkfDV2FPT0WU
SK-OV-3 NEnRXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLROmRvUUN3ME24MlQ3PzZ3IN88US=> NWDXUolEW0GQR1XS
KNS-62 NGfXUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DVe2lEPTB;OD61NVc3OSEQvF2= MnvOV2FPT0WU
GOTO NXLXT|hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnXV|RPUUN3ME24MlU4PjN3IN88US=> M1zINXNCVkeHUh?=
8305C M4PvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRThwN{C0PFQh|ryP NEn3SmNUSU6JRWK=
RPMI-2650 M4jvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRThwN{G5OVUh|ryP MYnTRW5ITVJ?
NEC8 M4Pid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRThwN{SzNFch|ryP Mn[3V2FPT0WU
KYSE-450 M{jmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme0TWM2OD16Lki2OVQ5KM7:TR?= NEjDToVUSU6JRWK=
RMG-I Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXKTWM2OD17LkG0NFU5KM7:TR?= M3PXN3NCVkeHUh?=
CAKI-1 NWHz[IY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTlwM{G5O|kh|ryP NWTKfFdVW0GQR1XS
KYSE-510 NFHYRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLqdHlKSzVyPUmuN|U4PzhizszN NUjPOYMyW0GQR1XS
A4-Fuk M2fUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\NfGVKSzVyPUmuN|Y4ODFizszN NFTGUnVUSU6JRWK=
AN3-CA Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn3VW9TUUN3ME25MlQ2PDR2IN88US=> M13u[3NCVkeHUh?=
SK-N-DZ M1roe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX6xT2s{UUN3ME25MlczQDR7IN88US=> NUfEZYlVW0GQR1XS
HSC-2 M{LIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTlwN{[2Nlkh|ryP MYjTRW5ITVJ?
EW-1 NEXvW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjxTWM2OD17Lke5N|Y6KM7:TR?= NF[zVmdUSU6JRWK=
D-566MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG0S4hRUUN3ME25Mlg{PjZ2IN88US=> Mo\DV2FPT0WU
COLO-792 M3rOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LnWWlEPTB;OT65PFc1PiEQvF2= MVTTRW5ITVJ?
TE-10 MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFyLkCzPVYh|ryP MnPlV2FPT0WU
NCI-H650 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rlcmlEPTB;MUCuOFI5PiEQvF2= M1ry[XNCVkeHUh?=
U-266 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Pwc2lEPTB;MUCuOFU2KM7:TR?= NHS3eoVUSU6JRWK=
Detroit562 NFXuRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\FWJpKSzVyPUGxMlA2OTVizszN MYDTRW5ITVJ?
NH-12 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XufGlEPTB;MUGuNVQ1PiEQvF2= MlLxV2FPT0WU
CO-314 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFzLkK4OFIh|ryP MXPTRW5ITVJ?
IST-MEL1 NHzLSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILQeoZKSzVyPUGxMlU{OjNizszN M4\WNXNCVkeHUh?=
KNS-81-FD M3nGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnkPJdlUUN3ME2xNU42PTJ5IN88US=> MkfnV2FPT0WU
SW1463 MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzFcZVKSzVyPUGxMlU6QDlizszN NVzyToZrW0GQR1XS
NCI-H23 M4\qU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PIXmlEPTB;MUGuOlU2OiEQvF2= NWjp[YZIW0GQR1XS
SK-MEL-2 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPCblhKSzVyPUGxMlcyQTdizszN MlG5V2FPT0WU
NB13 M2Txemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7BTWM2OD1zMj6xOFk2KM7:TR?= MWLTRW5ITVJ?
Daoy M3jOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\TRVFKSzVyPUGyMlI5PTZizszN NXG4VmJPW0GQR1XS
NCI-H1623 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq0TWM2OD1zMj6zPFAyKM7:TR?= M1XoPHNCVkeHUh?=
NMC-G1 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF{LkexO{DPxE1? NWfz[XlYW0GQR1XS
DK-MG M4m4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF{Lkm0PFIh|ryP MX\TRW5ITVJ?
TCCSUP Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXUR5dmUUN3ME2xN{4yOjh2IN88US=> MUfTRW5ITVJ?
SCC-15 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULFbmNqUUN3ME2xN{4zPjVzIN88US=> M4\kRnNCVkeHUh?=
NOS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn4TWM2OD1zMz6yPFk{KM7:TR?= MY\TRW5ITVJ?
RH-1 MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X4fGlEPTB;MUOuN|A{PyEQvF2= NXzCb5JtW0GQR1XS
SK-MEL-3 NGe5d5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELjfIZKSzVyPUGzMlM4OjhizszN MV;TRW5ITVJ?
NB5 NYG0SIllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLFd5B2UUN3ME2xN{41ODZ5IN88US=> MlziV2FPT0WU
SNU-387 NXzvS5VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF|LkWwO|Ih|ryP MojoV2FPT0WU
CAL-120 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF|Lk[3NVgh|ryP M3fVe3NCVkeHUh?=
Mo-T NF\UPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF|LkewO{DPxE1? NIPkTZFUSU6JRWK=
LNCaP-Clone-FGC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF|Lke5PVIh|ryP NHnwe2NUSU6JRWK=
CAN M{PNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfMcXRiUUN3ME2xOE4xOjh6IN88US=> M4jLXnNCVkeHUh?=
SK-MEL-30 NEHFbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G5dWlEPTB;MUSuNFY{KM7:TR?= NFLqPXhUSU6JRWK=
COLO-678 NYnVPXg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLiTWM2OD1zND6wPFIzKM7:TR?= MY\TRW5ITVJ?
SCC-9 NF\4NWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHxTWM2OD1zND6xNFIyKM7:TR?= M2nZRXNCVkeHUh?=
KINGS-1 M13ZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofJTWM2OD1zND6xOFAzKM7:TR?= MXPTRW5ITVJ?
SL-513 NVz4dVFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\4UINKSzVyPUG0MlE5PyEQvF2= NV7WeZZZW0GQR1XS
HLE NVrq[2xET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3oTWM2OD1zND6zPFUzKM7:TR?= MoDEV2FPT0WU
SW1573 M4nGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfKeJVKSzVyPUG0MlQ1OzVizszN M{LGdXNCVkeHUh?=
KYSE-140 NVfaUVg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7CWJZYUUN3ME2xOE43OzJ5IN88US=> MkXvV2FPT0WU
SK-PN-DW Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnEcHZKSzVyPUG0MlgxODFizszN M3LncHNCVkeHUh?=
A253 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF3LkC2NlUh|ryP MX;TRW5ITVJ?
CAL-12T MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH5TWM2OD1zNT60OlYzKM7:TR?= NIH2S3pUSU6JRWK=
COLO-679 NVvvUoxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLmcW4{UUN3ME2xOU44Pjh|IN88US=> MmW1V2FPT0WU
UACC-257 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TKc2lEPTB;MU[uNVIxOSEQvF2= MYPTRW5ITVJ?
U-87-MG Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF4LkO1NlMh|ryP MX\TRW5ITVJ?
HCC1806 Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF4LkewO|Eh|ryP NFGxWYJUSU6JRWK=
NCI-H2170 M3;Yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T6SGlEPTB;MUeuNlQ1QCEQvF2= MX\TRW5ITVJ?
AGS Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfUOINKSzVyPUG3MlM5ODhizszN MmrSV2FPT0WU
MEL-HO NFn3O5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy5cndKSzVyPUG3Mlc2ODNizszN MUPTRW5ITVJ?
SW48 NWC4bGxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF5Lke3NVYh|ryP MmOzV2FPT0WU
HuP-T4 NVOwOIw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWyTWM2OD1zOD6wNlA3KM7:TR?= M1n3RXNCVkeHUh?=
NCI-H720 NHXGOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF6LkG0NFIh|ryP MmnrV2FPT0WU
RCC10RGB NGrXdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF6LkG2PVch|ryP Moe4V2FPT0WU
HD-MY-Z MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfESlByUUN3ME2xPE4zOjV2IN88US=> NV3qR5VUW0GQR1XS
A427 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV73RpFYUUN3ME2xPE42ODl2IN88US=> M3KzNHNCVkeHUh?=
HCC2998 M3Wxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;1TWM2OD1zOD62NFUyKM7:TR?= M{H4ZnNCVkeHUh?=
EPLC-272H NW\iclk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;4b3J2UUN3ME2xPU4xPDN2IN88US=> NEPz[INUSU6JRWK=
C32 M3vmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDhTWM2OD1zOT6wOFUh|ryP NIfQN2hUSU6JRWK=
UMC-11 NUDtXo5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm3Ro9KSzVyPUG5MlIyOjNizszN M4XXcnNCVkeHUh?=
CaR-1 MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF7Lk[4NFQh|ryP NV;abYl4W0GQR1XS
KYSE-410 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H2bWlEPTB;MUmuPVE{QSEQvF2= MmL3V2FPT0WU
HuCCT1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJyLk[yPVQh|ryP MUfTRW5ITVJ?
LB996-RCC NIfwR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXweGpZUUN3ME2yNE44OTZ6IN88US=> NWjqRoRJW0GQR1XS
KYSE-70 NULhbmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJyLkiwOVkh|ryP Mn3SV2FPT0WU
CAL-72 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF34OWFKSzVyPUKwMlkyPSEQvF2= MoDzV2FPT0WU
Capan-2 M2rkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zCUmlEPTB;MkGuNFQyOyEQvF2= Ml3HV2FPT0WU
PANC-08-13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7nTWM2OD1{MT6yOVE2KM7:TR?= NV;KenluW0GQR1XS
SBC-1 NGG1TmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES5OJpKSzVyPUKxMlMxQDFizszN MWDTRW5ITVJ?
MFM-223 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS1TWM2OD1{MT6zN|QzKM7:TR?= M1O0PHNCVkeHUh?=
BB49-HNC M3i2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJzLkW3NVYh|ryP Ml3wV2FPT0WU
SH-4 M3XDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDETWM2OD1{MT62OlE5KM7:TR?= MmjyV2FPT0WU
HuO9 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrZPWx4UUN3ME2yNU46QDJ3IN88US=> NXT6WFZoW0GQR1XS
AM-38 NFWzNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPGUWYyUUN3ME2yNk4xPDh3IN88US=> MkTCV2FPT0WU
A431 NFmyT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJ|LkKxNVkh|ryP NIO0NFlUSU6JRWK=
YAPC NGewR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ|LkK2OVEh|ryP NXuxZpNrW0GQR1XS
LU-139 M3HtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ|LkS4NFkh|ryP MXrTRW5ITVJ?
HEC-1 M3;Fd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLZSYI4UUN3ME2yN{41QTN5IN88US=> NWfFUXh{W0GQR1XS
SCC-25 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ2LkOwNFYh|ryP MV\TRW5ITVJ?
HT-29 NHPFWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXPWnBwUUN3ME2yOE4{QDJ|IN88US=> M37SSHNCVkeHUh?=
PC-14 NHnKZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnyb5YxUUN3ME2yOE43PTdzIN88US=> M3\xO3NCVkeHUh?=
Calu-6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmwTWM2OD1{NT61NFcyKM7:TR?= M1e1cXNCVkeHUh?=
SJRH30 NHHsbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vmdGlEPTB;MkWuOlQ6PiEQvF2= NVHxVm95W0GQR1XS
ChaGo-K-1 NXzNNVV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T5OGlEPTB;Mk[uNVYzQSEQvF2= NVHrRoE{W0GQR1XS
IA-LM Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe2RWFKSzVyPUK2MlM3PDVizszN MWTTRW5ITVJ?
GP5d MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfq[|ZKSzVyPUK2MlQ1QTFizszN MWrTRW5ITVJ?
NCI-H2291 NVHiZ2pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPZcVNlUUN3ME2yOk43PTRzIN88US=> NVnMfG9NW0GQR1XS
BALL-1 NYTmSG9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ4LkmzPVch|ryP NXjxfHJPW0GQR1XS
HCC1954 NF;GU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJ4Lkm4NFgh|ryP MonQV2FPT0WU
NCI-H2452 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Cc4hKSzVyPUK3MlQyPjNizszN NFzl[mRUSU6JRWK=
LU-99A M4flSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\xUGlEPTB;MkeuOVU5OiEQvF2= MX3TRW5ITVJ?
NTERA-S-cl-D1 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrjb4FKSzVyPUK3MlczQTlizszN M{O4fHNCVkeHUh?=
PANC-10-05 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkGxTWM2OD1{Nz63O|c2KM7:TR?= NVnBR4dZW0GQR1XS
NCI-H2405 MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1GzZWlEPTB;MkeuPVM5PyEQvF2= MnPPV2FPT0WU
MDA-MB-415 NHPuNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzkZ25wUUN3ME2yPE41OTN5IN88US=> MYnTRW5ITVJ?
NCI-H2342 NVvLZZhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCzUm9sUUN3ME2yPE42OjhzIN88US=> M1L0bHNCVkeHUh?=
TGBC24TKB NXq1TpdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITS[oxKSzVyPUK4MlcyOTdizszN M{LUVHNCVkeHUh?=
LU-134-A NYniWJpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jM[mlEPTB;MkiuPVI3OSEQvF2= M{DhcXNCVkeHUh?=
SCC-4 NF3W[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNzLkC0PVQh|ryP NVq0cJhxW0GQR1XS
Saos-2 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPXTWM2OD1|MT65N|A3KM7:TR?= MljCV2FPT0WU
RERF-LC-MS NUX2UoU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHWTWM2OD1|Mj64NlMyKM7:TR?= Mk\XV2FPT0WU
M14 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\OPY5KSzVyPUOyMlk4PjRizszN MVvTRW5ITVJ?
HPAF-II NHr0d3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTN|LkWwNVEh|ryP MVPTRW5ITVJ?
NCI-H1755 Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN2LkOzNFUh|ryP MYjTRW5ITVJ?
D-392MG M4DwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLzTIxSUUN3ME2zOU45Pjd2IN88US=> MWTTRW5ITVJ?
A704 NVfSVGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i5emlEPTB;M{[uNFQzPyEQvF2= MVfTRW5ITVJ?
CP50-MEL-B M3vTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqzTWM2OD1|Nj6xPVEyKM7:TR?= MlHWV2FPT0WU
EW-18 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH3TWM2OD1|Nj60OVIh|ryP M1jVRXNCVkeHUh?=
WM-115 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTN4LkiwPVkh|ryP MlnRV2FPT0WU
LU-65 Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[3TWM2OD1|Nz6xOFE4KM7:TR?= M37RTXNCVkeHUh?=
NCI-H1563 M3qxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHoTWM2OD1|Nz6yOFg1KM7:TR?= M4rEPXNCVkeHUh?=
DBTRG-05MG NVHKR4EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HjVWlEPTB;M{iuNFY6OSEQvF2= Ml7nV2FPT0WU
NCI-H630 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rIT2lEPTB;M{iuOFcyPCEQvF2= MnT4V2FPT0WU
NCI-H1155 NYDPeFB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN7LkK0NkDPxE1? M2j0T3NCVkeHUh?=
OVACR-3 MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DodWlEPTB;M{muPVE6PSEQvF2= MV3TRW5ITVJ?
OAW-42 NIPPPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTRyLkSyOVgh|ryP M3nn[HNCVkeHUh?=
JVM-2 M1fPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PScWlEPTB;NEGuNlQyPSEQvF2= NXrac2d{W0GQR1XS
C3A NFjTOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HyOWlEPTB;NEGuN|Q1PyEQvF2= NXTjNW8{W0GQR1XS
HT55 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR{LkK4OFEh|ryP Ml3kV2FPT0WU
OVCAR-4 NWDKNG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rHSGlEPTB;NEKuNlk4PCEQvF2= NInOWWtUSU6JRWK=
MEG-01 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPPfmx6UUN3ME20Nk41PjF4IN88US=> MmnzV2FPT0WU
NCI-H82 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTR|Lkm4PVIh|ryP M4mzeXNCVkeHUh?=
JEG-3 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TSXmlEPTB;NESuPVQ4KM7:TR?= MV3TRW5ITVJ?
BPH-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr3[2lKSzVyPUS2MlM6QThizszN M3niOXNCVkeHUh?=
MPP-89 NWDQWYR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTR5LkK4PVgh|ryP MnS2V2FPT0WU
ALL-PO MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\0TWM2OD12Nz60NVg5KM7:TR?= MnfuV2FPT0WU
HT NF7CcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXzd2hXUUN3ME20O{41QTJizszN NHn0dZBUSU6JRWK=
NCI-H2347 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTR6LkC3NVUh|ryP NXXtRmhPW0GQR1XS
A2780 NESxZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jCUGlEPTB;NEmuOFIzQCEQvF2= NI\pV|dUSU6JRWK=
KARPAS-299 NIPIU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTR7LkWxNVkh|ryP NFK4dolUSU6JRWK=
NCI-H1651 MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jEO2lEPTB;NEmuPFgzOSEQvF2= NV3OeZlpW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol slightly soluble or insoluble
In vivo Saline 20 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID